AHRÉN BO ET AL: "Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial", THE LANCET / DIABETES & ENDOCRINOLOGY, vol. 5, no. 5, 1 May 2017 (2017-05-01), UK, pages 341 - 354, XP093240282, ISSN: 2213-8587, DOI: 10.1016/S2213-8587(17)30092-X (B1)

ANON: "Company Announcement No 40/2012 Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue", 21 June 2012 (2012-06-21), pages 1 - 4, XP093133939, Retrieved from the Internet <URL:https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=2286> (B1)

ANON: "Protocol of clinical trial NCT00696657 entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide", v8 22.09.2011", 22 September 2011 (2011-09-22), pages 1 - 5, XP093063232, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT00696657?tab=history&a=8> [retrieved on 20230712] (B1)

BHANSALI ET AL: "Historical Overview of Incretin Based Therapies", JAPI, vol. 58, 1 June 2010 (2010-06-01), pages 1 - 14, XP055592040 (B1)

WO-A2-2012/177929 (B1)

WO-A1-2011/138421 (B1)

WO-A1-2012/107476 (B1)

WO-A2-2010/092163 (B1)

S. MADSBAD ET AL: "An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future", DIABETES, OBESITY AND METABOLISM, vol. 13, no. 5, 24 March 2011 (2011-03-24), pages 394 - 407, XP055043880, ISSN: 1462-8902, DOI: 10.1111/j.1463-1326.2011.01357.x (B1)